Masimo Corporation $MASI Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. lowered its position in shares of Masimo Corporation (NASDAQ:MASI) by 21.8% in the third quarter, Holdings Channel reports. The firm owned 107,941 shares of the medical equipment provider’s stock after selling 30,149 shares during the period. JPMorgan Chase & Co.’s holdings in Masimo were worth $15,927,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Tudor Investment Corp ET AL purchased a new position in Masimo in the third quarter valued at approximately $4,669,000. Allworth Financial LP grew its stake in Masimo by 133.9% during the third quarter. Allworth Financial LP now owns 905 shares of the medical equipment provider’s stock worth $134,000 after buying an additional 518 shares during the period. Swiss Life Asset Management Ltd grew its stake in Masimo by 78.8% during the third quarter. Swiss Life Asset Management Ltd now owns 2,173 shares of the medical equipment provider’s stock worth $321,000 after buying an additional 958 shares during the period. Coldstream Capital Management Inc. increased its position in shares of Masimo by 17.2% in the third quarter. Coldstream Capital Management Inc. now owns 2,668 shares of the medical equipment provider’s stock worth $394,000 after acquiring an additional 391 shares in the last quarter. Finally, Danske Bank A S purchased a new position in shares of Masimo in the 3rd quarter valued at $59,000. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Price Performance

Shares of MASI stock opened at $176.89 on Friday. The firm has a fifty day simple moving average of $159.23 and a 200-day simple moving average of $148.12. The company has a market capitalization of $9.50 billion, a PE ratio of -16.78, a price-to-earnings-growth ratio of 1.80 and a beta of 1.21. Masimo Corporation has a twelve month low of $125.94 and a twelve month high of $179.00. The company has a current ratio of 2.49, a quick ratio of 1.47 and a debt-to-equity ratio of 0.72.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on MASI. Piper Sandler cut shares of Masimo from an “overweight” rating to a “hold” rating and set a $180.00 price target for the company. in a research report on Tuesday, February 17th. Wells Fargo & Company raised Masimo to a “hold” rating in a research report on Wednesday, March 18th. Weiss Ratings restated a “sell (d)” rating on shares of Masimo in a research note on Thursday, January 22nd. BTIG Research lowered Masimo from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 18th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a report on Monday, December 1st. One analyst has rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $181.17.

Masimo Company Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.